机构：[1]Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.[2]Guangdong Provincial Center for Disease control and Prevention, Guangzhou, 510006, China.[3]Shunde Hospital of Guangzhou University of Chinese Medicine, Shunde, Guangdong, 510000, China
Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.
基金：
It is thankful that Guangdong Province Universities and
Colleges Pearl River Scholar Funded Scheme (No. Guochao (No. 81773580), The Department of Science and Technology of
Guangdong Province, China (No. 2020111107001), The
Department of Education of Guangdong Province, China (No.
2020KZDZX1057), and Guangdong Key Laboratory for
Translational Cancer Research of Chinese Medicine (No.
2018B030322011) offered financial support for this work.
语种：
外文
PubmedID：
第一作者：
第一作者机构：[1]Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
通讯作者：
通讯机构：[1]Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.[3]Shunde Hospital of Guangzhou University of Chinese Medicine, Shunde, Guangdong, 510000, China
推荐引用方式(GB/T 7714)：
Qi Xiaoxiao,Ke Bixia,Feng Qian,et al.Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.[J].Chemical communications (Cambridge, England).2020,doi:10.1039/d0cc03263h.
APA：
Qi Xiaoxiao,Ke Bixia,Feng Qian,Yang Deying,Lian Qinghai...&Liao Guochao.(2020).Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection..Chemical communications (Cambridge, England),,
MLA：
Qi Xiaoxiao,et al."Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.".Chemical communications (Cambridge, England) .(2020)
